www.fdanews.com/articles/114015-glaxo-buys-ucb-8217-s-emerging-market-160-activities

Glaxo Buys UCB’s Emerging Market Activities

January 23, 2009

The world’s second-largest pharmaceutical group GlaxoSmithKline Plc has agreed to buy Belgian peer UCB’s operations in a number of emerging markets for 515 million euros (484 million pounds).
International Herald Tribune